126 related articles for article (PubMed ID: 30056546)
21. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
[TBL] [Abstract][Full Text] [Related]
22. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2 -microglobulin.
Melchardt T; Troppan K; Weiss L; Hufnagl C; Neureiter D; Tränkenschuh W; Hopfinger G; Magnes T; Deutsch A; Neumeister P; Hackl H; Greil R; Pichler M; Egle A
Br J Haematol; 2015 Jan; 168(2):239-45. PubMed ID: 25236324
[TBL] [Abstract][Full Text] [Related]
23. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
Prochazka KT; Melchardt T; Posch F; Schlick K; Deutsch A; Beham-Schmid C; Weiss L; Gary T; Neureiter D; Klieser E; Greil R; Neumeister P; Egle A; Pichler M
Br J Cancer; 2016 Nov; 115(10):1264-1272. PubMed ID: 27764838
[TBL] [Abstract][Full Text] [Related]
24. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
[TBL] [Abstract][Full Text] [Related]
26. Posttreatment PET/CT Rather Than Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: A Prospective Study Comparing PET/CT with Conventional Imaging.
Bakhshi S; Bhethanabhotla S; Kumar R; Agarwal K; Sharma P; Thulkar S; Malhotra A; Dhawan D; Vishnubhatla S
J Nucl Med; 2017 Apr; 58(4):577-583. PubMed ID: 27754902
[TBL] [Abstract][Full Text] [Related]
27. 18F-FDG PET/CT for Prognostic Stratification of Patients With Extranodal Natural Killer/T-Cell Lymphoma.
Qin C; Yang S; Sun X; Xia X; Li C; Lan X
Clin Nucl Med; 2019 Mar; 44(3):201-208. PubMed ID: 30624268
[TBL] [Abstract][Full Text] [Related]
28. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β
Montalbán C; Díaz-López A; Dlouhy I; Rovira J; Lopez-Guillermo A; Alonso S; Martín A; Sancho JM; García O; Sánchez JM; Rodríguez M; Novelli S; Salar A; Gutiérrez A; Rodríguez-Salazar MJ; Bastos M; Domínguez JF; Fernández R; Gonzalez de Villambrosia S; Queizan JA; Córdoba R; de Oña R; López-Hernandez A; Freue JM; Garrote H; López L; Martin-Moreno AM; Rodriguez J; Abraira V; García JF;
Br J Haematol; 2017 Mar; 176(6):918-928. PubMed ID: 28106247
[TBL] [Abstract][Full Text] [Related]
29. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas.
Sonnen R; Schmidt WP; Müller-Hermelink HK; Schmitz N
Br J Haematol; 2005 May; 129(3):366-72. PubMed ID: 15842660
[TBL] [Abstract][Full Text] [Related]
30. Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma.
Hong J; Kim SJ; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Lee HS; Yun HJ; Lee SI; Kim MK; Yi JH; Lee JH; Kim WS; Suh C
Oncotarget; 2017 Nov; 8(54):92171-92182. PubMed ID: 29190906
[TBL] [Abstract][Full Text] [Related]
31. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
[TBL] [Abstract][Full Text] [Related]
32. Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma.
Huang H; Xiao F; Han X; Zhong L; Zhong H; Xu L; Zhu J; Ni B; Liu J; Fang Y; Zhang M; Shen L; Wang T; Liu J; Shi Y; Chen Y; Zheng L; Liu Q; Chen F; Wang J
Nucl Med Commun; 2016 Jul; 37(7):689-98. PubMed ID: 27244584
[TBL] [Abstract][Full Text] [Related]
33. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
[TBL] [Abstract][Full Text] [Related]
34. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
[TBL] [Abstract][Full Text] [Related]
35. Tumor necrosis at FDG-PET is an independent predictor of outcome in diffuse large B-cell lymphoma.
Adams HJA; de Klerk JMH; Fijnheer R; Heggelman BGF; Dubois SV; Nievelstein RAJ; Kwee TC
Eur J Radiol; 2016 Jan; 85(1):304-309. PubMed ID: 26515992
[TBL] [Abstract][Full Text] [Related]
36. Validation of the international prognostic index in working formulation group A low-grade non-Hodgkin's lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry.
Stelitano C; Baldini L; Pieresca C; Callea V; Angrilli F; Clò V; Partesotti G; Merli F; Cavanna L; Morabito F; Federico M; Brugiatelli M; Silingardi V
Haematologica; 2000 Feb; 85(2):154-9. PubMed ID: 10681722
[TBL] [Abstract][Full Text] [Related]
37. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
Akkas BE; Vural GU
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
[TBL] [Abstract][Full Text] [Related]
38. Validation of the International Prognostic Index and Subsequent Revisions for Diffuse Large B-Cell Lymphoma in Patients From the Middle East and North Africa Region.
Alamer F; Alamir A; Alqahtani A; Alkabli AM; Alshabib H; Damlaj M
Cureus; 2020 Aug; 12(8):e9620. PubMed ID: 32923221
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of the enhanced International Prognostic Index (NCCN-IPI) for cases with diffuse large B-cell lymphoma].
Yamada A; Tamura H; Asayama T; Moriya K; Okuyama N; Kondo-Onodera A; Hamada Y; Ishibashi M; Yokose N; Tanosaki S; Inokuchi K
Rinsho Ketsueki; 2015 Jul; 56(7):915-8. PubMed ID: 26256931
[TBL] [Abstract][Full Text] [Related]
40. Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma.
Ochi Y; Kazuma Y; Hiramoto N; Ono Y; Yoshioka S; Yonetani N; Matsushita A; Imai Y; Hashimoto H; Ishikawa T
Ann Hematol; 2017 Jan; 96(1):1-8. PubMed ID: 27641425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
